BiomeSense is revolutionizing human microbiome research by creating novel tools to track, analyze, and store daily microbiome profiles of clinical trial participants, providing vastly more data than is possible with current tools, all for a fraction of the cost. This gives investigators far deeper insight into how the microbiome influences and is influenced by clinical interventions.
Kevin Honaker – Co-Founder & Chief Executive Officer
Dr. Jack Gilbert – Co-Founder
Dylan Nichols – Chief Technology Officer
Dr. Savas Tay – Scientific Advisor & Co-Founder
Bio-Me has created a novel qPCR-based platform (in collaboration with Thermo Fisher Scientific) called Precision Microbiome Profiling (PMP™), which enables rapid (100-200 samples in 2 hours), accurate, and highly reproducible microbiome analysis down to the strain level. The output consists of ready-to-use results that can be adapted into clinical practice.
Thanks to Bio-Me’s proprietary pipeline, specific assays at the species and strain level are developed for the relevant microbial targets, resulting in customized disease, or drug-specific profiling solutions. In addition, Bio-Me offers an off-the-shelf product (PMP™ Broad Panel), which consists of approximately 100 unique assays for specific bacterial targets screening the general condition of the gut microbiome.
Bio-Me is collaborating with key opinion leaders in the microbiome space and leading academic institutions in Europe and the US. Our partners are, amongst others, pharma and biotech companies developing next-generation microbiome-modifying drugs. We support their clinical development programs with our expertise, microbiome profiling solutions, and our access to fecal samples from 13 300 individuals (including anonymized medical registries with more than 6 000 different health parameters) through our special collaboration with HUNT4.
Bio-Me collaborates on trials for several disease areas, such as cancer immuno-oncology, IBD, and colorectal cancer.
Warren Flood, PhD – Chief Executive Officer
Morten Isaksen, PhD – Founder and Chief Innovation Officer
Jean-Marc Billod, PhD – Chief Operating Officer
Runar Vige, MSc MBA – Chief Business Officer
Selected Board members
Carl Christian Gilhuus-Moe – former CEO Dynal (Dynabeads®)
Arne Materna – former VP of Product, CosmosID
Heiner Dreismann – former President and CEO of Roche Molecular Systems
Charles Stabell – former Assistant Professor Stanford University
About Genetic Analysis
Genetic Analysis (GA) is a molecular diagnostic company with core focus within microbiome and has developed and launched the GA-map® Platform for gut microbiome analysis. The first marker is the GA-map Dysbiosis Test, the first documented CE marked routine test to identify and characterize the gut microbiota composition, initially targeted at IBS and IBD patients.
The results are immediately compared to a clinical validated normal healthy population through the advanced GA-map® software algorithm. This enables immediate results without any further bioinformatics work needed. GA-map® is currently the only routine diagnostic tool for microbiota.
Commercialisation has started on the European and US market and the GA-map® Test platform will increase the efficiency in the Lab and provide customers with superb quality results that is unique within the microbiome diagnostics area.
GA collaborates with pharma companies and academia in research projects for product documentation, new marker discovery and clinical research.
GA has new biomarker development projects ongoing in order to utilize the platform for other disease areas and has a unique bio-Bank with more than 7000 samples within different cohorts i.e; Healthy normals, IBD, Cdiff, IBS, Diabetes T2, RA, Parkinson.
Ronny Hermansen, CEO
Christina Casén, Director of Clinical and Medical Affairs
Finn Terie Hegge, CTO, Head of Operations
Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized non-frozen, oral capsule formulation, which is currently moving into a Phase 2 IND trial for the prevention of recurrent C. diff infection having completed an investigator sponsored Phase 1 study. In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ platform. The MRT™ platform is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format.
Recurrent C. diff prevention
Pediatric Ulcerative Colitis
Multi-drug Resistant UTI
Lee Jones – Founder, President, and Chief Executive Officer
Dale N. Gerding, M.D., MACP, FIDSA, FSHEA – Chief Medical Officer
Ken F. Blount, Ph.D. – Chief Scientific Officer
Edward S. Burd, Ph.D. – Head of Regulatory Affairs
Nancy Timm, VP of Finance and Operations
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma.
Inflammatory bowel disease
Eric Shaff – President, Chief Executive Officer
John Aunins, Ph.D. – Executive Vice President, Bioprocess & Manufacturing and Chief Technology Officer
Thomas J. DesRosier, Esq. – Executive Vice President, Chief Legal Officer and Secretary
Matthew Henn, Ph.D. – Executive Vice President, Chief Scientific Officer
Lisa von Moltke, M.D. – Executive Vice President, Chief Medical Officer
Jim Weston – Senior Vice President, Regulatory Affairs
Servatus Ltd is devoted to creating safe, effective and reliable microbiome-based therapeutic drugs to treat a number of chronic and debilitating autoimmune diseases, as well as non-antibiotic treatments for bacterial infections. First established in 2012, Servatus Biopharmaceuticals already has a number of clinical trials underway, trialing microbial-based biotherapeutic drugs for a range of chronic, inflammatory autoimmune conditions, such as Rheumatoid Arthritis, atopic dermatitis, and bowel diseases, as well as gastrointestinal bacterial infections. Servatus targets conditions which are proven to be associated with microbiome dysbiosis and the accompanying immune dysregulation. The unique strains developed at Servatus have demonstrated bioactive properties that inhibit pathogenic bacterial growth, modulate immune system responses and regulate the inflammatory signal pathways. Servatus also has a second research and development arm directed at engineering existing therapeutic proteins that have demonstrated clear clinical utility in human disease. Through rational redesign of key features Servatus improves specific protein characteristics such as bioavailability, half-life, or biological potency. The novel variants are then cloned and expressed in clinically relevant amounts for medicinal applications. Servatus Biopharmaceuticals derives its name from Saint Servatus, a churchman and diplomat in the 4th Century who was invoked as a patron saint for his healing powers for a range of ailments, including Rheumatism.
Helicobacter Pylori infection
Functional Idiopathic Constipation (IBS-IC)
Dr Wayne Finlayson, BSc (Hons), Ph.D – Founder and Chief Executive Officer
Mark Williams, BComm., LLB (Hons), Law. – Executive Director and Chief Financial Officer
Dr Michael Vitale Ph.D,. MBA. – Chairman
Hugh Alsop, MBA., BSc. – Director
Dr Wolf Hanisch, BSc., Ph.D. – Co-founder
Jeremy Martineau, MA (Hons). – Company SecretaryMedical Advisory Board
Prof Gerald Holtman, MD., PhD., MBA., FRACP., FRCP., FAHMS.
Dr/Prof Peter Nash, MD., FRACP., MBBS.
Dr/Prof Michael Freeman MD., MBBS.
Siolta Therapeutics is a clinical-stage biotech company on a mission to alleviate the suffering of millions impacted by chronic inflammatory diseases through novel microbiome-based medicines. Siolta leverages its deep knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases. The company’s blended expertise from microbiology, immunology, and bioinformatics supports the development of a multifaceted platform, integrating ecosystems approaches and precision medicine concepts to advance the future of medicine. Currently focused on the clinical development of their lead product for the prevention and treatment of allergic asthma, Siolta’s holistic, microbiome-based strategy represents a new frontier in the pursuit of tailored, clinically differentiated microbial therapeutics.
Prevention of Allergic Disease
Nikole Kimes, Ph.D. – Founder, Chief Executive Officer
Richard Shames, M.D. – Consulting CMO
Ricardo Valladares, Ph.D. – Vice President of Research and Development
Susan Lynch, Ph.D. – Founder, Member of the Board of Directors
Samir Kaul, MBA – Member of the Board of Directors
Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com
Microbiome-related Target Indications
Inflammatory bowel diseases
Complications of Liver disease
Vedanta Biosciences is developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria. Vedanta Biosciences is a leader in the microbiome field with capabilities and deep expertise to discover, develop, and manufacture live bacteria drugs. These include what is believed to be the largest collection of human microbiome-associated bacterial strains, a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form.
Vedanta Biosciences’ pioneering work, in collaboration with its scientific co-founders, has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others. These advances have been published in leading peer-reviewed journals including Science (multiple), Nature (multiple), Cell and Nature Immunology. Vedanta Biosciences has harnessed these biological insights and its capabilities to generate a pipeline of programs in infectious disease, autoimmune disease, allergy, and immune-oncology.
Inflammatory Bowel Disease
Multi-drug Resistant Organisms
Bernat Olle, Ph.D. – Chief Executive Officer
Dan Couto – Chief Operations Officer
Jeffrey Silber, M.D. – Chief Medical Officer
Anne Kuan – SVP, Regulatory Affairs
Microba Life Sciences
About Microba Life Sciences
Microba Life Sciences is a pre-clinical precision microbiome science company taking a human-first, data-driven approach to therapeutic discovery. Powered by precision analysis, Microba’s therapeutic discovery platform uses human data and leading informatic approaches to connect microbial genotype to human phenotype. Pioneered by our founders, our unique approach to culturing novel bacteria through genome-directed isolation provides us with novel disease-relevant bacterial isolates. The lead candidates derived from the human first, data driven approach have achieved excellent results and are being prepared for human trials.
Inflammatory Bowel Disease
Cancer – Immune Checkpoint Inhibitor Adjuvant Therapy
Professor Ian Frazer AC, Chair of Medical Advisory Board
Professor Gene Tyson, Chief Scientist, Co-Founder
Professor Phil Hugenholtz, Chief Scientist, Co-Founder
Blake Wills, Chief Executive Officer
Dr Luke Holtham Reid, President
Associate Professor Lutz Krause, Head of Data-mining and Artificial Intelligence
Dr Páraic Ó Cuív, Lead Live Biotherapeutics
Associate Professor Jake Begun, Medical Advisory Board, IBD Advisory Panel
About Alveolus Bio
Alveolus Bio is developing safe, targeted, and efficacious therapies for lung diseases. Founded and managed by physician scientists based on 15+ years of research into neutrophilic inflammation and microbial dysbiosis associated with chronic pulmonary disease, Alveolus Bio is focused on lung diseases of infancy, childhood, and adulthood. Specifically, Alveolus Bio’s drug development pipeline includes breakthrough therapeutics for respiratory indications such as Chronic Obstructive Pulmonary Disease (COPD), Bronchopulmonary Dysplasia (BPD), and Idiopathic Pulmonary Fibrosis (IPF), as well as a discovery program for Pulmonary Arterial Hypertension (PAH). The founders have assembled a team of leading researchers in the fields of respiratory medicine, microbiome science, and drug delivery modalities to pioneer novel biotherapeutics and delivery models.
Chronic Obstructive Pulmonary Disease (COPD)
Bronchopulmonary Dysplasia (BPD)
Idiopathic Pulmonary Fibrosis (IPF)
Pulmonary Arterial Hypertension (PAH)
C Vivek Lal MD FAAP, Founder and CEO